BIEL MAY NOW BE CASH FLOW POSITIVE!!!
Clarifying the $600k Interest Expense: Why BIEL is Closer to Cash-Flow Positive Than People Think
The $600k interest expense line and what it means for the timeline to profitability. Let’s break down the actual math here, because the reality is much more bullish than the headline net loss suggests.
1. The $600k Interest Illusion (GAAP vs. Reality)
Most people look at the $600k interest line and think the company is bleeding cash to lenders. It isn't.
The Whelan Family Loans: As we know, the Whelan family (majority insiders) has repeatedly agreed to waive/forgo cash interest payments on their related-party loans to keep BIEL alive.
The Accounting Rule: Under GAAP accounting, BIEL must record this interest on the income statement as an expense, even though the family isn't taking a dime of it. On the Cash Flow statement, this is added back as a non-cash expense.
The Rest: The only actual cash interest leaving the company goes to smaller, third-party short-term/convertible notes used for inventory cycles.
2. The Path to Cash-Flow Positive vs. Net Profitability
Because of BIEL’s insane ~85% gross margins on ActiPatch, the company is actually operationally profitable on a tiny scale. It only takes a modest revenue bump to cross the finish line.
To Turn Cash-Flow Positive (Target: Mid/Late 2026): Since the family isn’t demanding cash for their interest, BIEL only needs to generate enough physical cash to cover basic overhead ($350k/year) and manufacturing. The initial stocking orders from the Taiwan expansion (May 2026) and the Electrome distribution deal (June 2026) should provide the cash influx to flip operational cash flow positive this year.
To Turn Net Profitable on Paper (Target: Mid/Late 2027): To erase the GAAP "paper" net loss completely, BIEL needs its annual revenue run-rate to cross roughly $1.5 Million.
The Electrome Deal is the Inflection Point
At $1.5M in annual revenue, an 85% gross margin yields $1.27M in gross profit. Subtract the $350k lean operating expenses, and you are left with $920k—more than enough to fully absorb that $600k accounting interest line and post a green bottom line.
With Electrome targeting 3,700 retail pharmacies by Q3 2026 for the PAINKILLER™ platform, hitting that $1.5M revenue baseline by 2027 is highly achievable.
Bottom Line: Don't sweat the paper net loss—look at the Cash Flow from Operations line. If Electrome's upfront purchase orders hit the books like they should, the cash infusion will change the narrative here real quick!
Clarifying the $600k Interest Expense: Why BIEL is Closer to Cash-Flow Positive Than People Think
The $600k interest expense line and what it means for the timeline to profitability. Let’s break down the actual math here, because the reality is much more bullish than the headline net loss suggests.
1. The $600k Interest Illusion (GAAP vs. Reality)
Most people look at the $600k interest line and think the company is bleeding cash to lenders. It isn't.
The Whelan Family Loans: As we know, the Whelan family (majority insiders) has repeatedly agreed to waive/forgo cash interest payments on their related-party loans to keep BIEL alive.
The Accounting Rule: Under GAAP accounting, BIEL must record this interest on the income statement as an expense, even though the family isn't taking a dime of it. On the Cash Flow statement, this is added back as a non-cash expense.
The Rest: The only actual cash interest leaving the company goes to smaller, third-party short-term/convertible notes used for inventory cycles.
2. The Path to Cash-Flow Positive vs. Net Profitability
Because of BIEL’s insane ~85% gross margins on ActiPatch, the company is actually operationally profitable on a tiny scale. It only takes a modest revenue bump to cross the finish line.
To Turn Cash-Flow Positive (Target: Mid/Late 2026): Since the family isn’t demanding cash for their interest, BIEL only needs to generate enough physical cash to cover basic overhead ($350k/year) and manufacturing. The initial stocking orders from the Taiwan expansion (May 2026) and the Electrome distribution deal (June 2026) should provide the cash influx to flip operational cash flow positive this year.
To Turn Net Profitable on Paper (Target: Mid/Late 2027): To erase the GAAP "paper" net loss completely, BIEL needs its annual revenue run-rate to cross roughly $1.5 Million.
The Electrome Deal is the Inflection Point
At $1.5M in annual revenue, an 85% gross margin yields $1.27M in gross profit. Subtract the $350k lean operating expenses, and you are left with $920k—more than enough to fully absorb that $600k accounting interest line and post a green bottom line.
With Electrome targeting 3,700 retail pharmacies by Q3 2026 for the PAINKILLER™ platform, hitting that $1.5M revenue baseline by 2027 is highly achievable.
Bottom Line: Don't sweat the paper net loss—look at the Cash Flow from Operations line. If Electrome's upfront purchase orders hit the books like they should, the cash infusion will change the narrative here real quick!
2
